Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Plus Therapeutics Inc.
Plus Therapeutics Announces Reverse Stock Split
May 2, 2026
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors
May 1, 2026
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
April 30, 2026
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
March 13, 2026
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
February 25, 2026
←
Previous Page
1
2
3